Myomo

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. It offers MyoPro, an upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myomo reports 9% revenue growth in Q1 2024 earnings call

Myomo's Q1 2024 performance reflects revenue growth driven by favorable CMS developments, with plans to double manufacturing capacity and achieve cash flow breakeven by Q4 2024.
The company's strategic strengths lie in its focus on the prevalence group, international expansion, and commitment to market leadership through increased output and R&D investments.
Challenges include managing operating expenses, scaling manufacturing capacity, and meeting revenue targets amidst market competition and reimbursement rate fluctuations.
Opportunities abound in international growth, market expansion in Germany, and the potential for accelerated U.S. revenue, supported by investments in resources and R&D.

Myomo excels in Q2 with record revenues and global expansion

Myomo's Q2 2024 performance reflects strong revenue growth, operational efficiency gains, and strategic expansion initiatives.
The company's strengths lie in international revenue generation, production facility expansion plans, and commitment to meeting product demand.
Challenges include scaling production while ensuring quality, monitoring advertising ROI, and balancing R&D with operational needs.
Opportunities arise from investor engagement, increased advertising, and continued innovation to drive market presence and revenue growth.

Myomo reports record Q3 revenue, eyes global expansion and market partnerships

Myomo's Q3 performance showcased robust revenue growth, pipeline expansion, and strategic partnerships, positioning the company for sustained success and global expansion.
While facing operational losses, Myomo's strengths in product innovation, market expansion, and capacity planning provide a solid foundation for future growth and profitability.
Challenges in cost management, market penetration, and regulatory compliance need to be addressed, but the company's proactive approach to expansion and partnerships bodes well for seizing growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The firm is also involved in selling products through various other sales channels including through orthotics and prosthetics providers, veterans’ administration, and to distributors in certain accounts and geographic markets. The company was founded by Stephen Kelly, John McBean, Mira Sahney, and Kailas N. Narendran on September 1, 2004 and is headquartered in Boston, MA.

FARO Technologies

As 2025 approaches, several promising micro-cap stocks are gaining attention for their potential to disrupt key industries. These companies, though small in market size, are making significant strides with innovative technologies and strategic advancements.

Top 3 Cutting-Edge Micro-Caps Set for 2025 Growth

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount.

Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in t.

Myomo, Inc. Announces Proposed Public Offering of Common Stock

Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.06 per share a year ago.

Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Product a.

Myomo Reports Record Third Quarter Financial and Operating Results

Myomo's business model is now sustainable due to CMS reclassifying MyoPro, leading to lump sum payments and consistent insurance coverage. Medicare Part B coverage has significantly improved Myomo's operating margin and accelerated its product sales growth. The development of an Orthopedic and Prosthetic clinic network will lower customer acquisition costs and create recurring sales, enhancing long-term growth & margins.

CMS Decision And O&P Network Build Out Make Myomo A Buy

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces it has entered into the first contracts that will allow MyoPro to be provided to patients covered by private insurance on an in-network basis. These new contracts are with Blue Cross Blue Shield of Massachusetts, a leading commercial and Medicare Advantage.

Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairm.

Myomo to Report Third Quarter Financial Results on November 6, 2024

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, president and chief executive officer, and David Henry, chief financial officer, will participate in a “Fireside Chat” at the 2024 Maxim Healthcare Virtual Summit. The virtual summit is being presented by Maxim Group LLC, from Octob.

Myomo to Participate in the 2024 Maxim Healthcare Virtual Summit

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the official launch of the Myomo Academy, a comprehensive learning management system for professionals in Orthotics & Prosthetics (O&P) and Rehabilitation. The Myomo Academy is being launched during the 2024 AOPA (American Orthotic and Prosthe.

Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be participating in two investor conferences during the month of September. Paul Gudonis, chairman and chief executive officer, and David Henry, chief financial officer, will present and host one-on-one meetings at the HC Wainwrig.

Myomo to Participate in Two Investor Conferences in September

Myomo, Inc. (NYSE:MYO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Scott Henry - AGP Anthony Vendetti - Maxim Group Edward Woo - Ascendiant Capital Ben Haynor - Lake Street Capital Markets Operator Good day and welcome to Myomo's Second Quarter of 2024 Earnings Call. All participants are in listen-only mode.

Myomo, Inc. (MYO) Q2 2024 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2024. Financial and operational highlights for the second quarter of 2024 include the following (all comparisons are with the second quarter of 2023 unless otherwise indicated): Product rev.

Myomo Reports Second Quarter 2024 Financial Results

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2024 on August 6, 2024. The Company will host a conference call the same day, Tuesday August 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chi.

Myomo to Report Second Quarter Financial Results on August 6, 2024

Ekso Bionics Hlds

ReWalk Robotics Ltd

An exciting, under-the-radar development is unfolding. I'm referring to the development of Robotic Exoskeletons, a phenomenon that could literally be life-changing to some.

The 3 Best Robotic Exoskeleton Stocks to Buy Now

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, reports preliminary revenues and operating metrics for the three months ended June 30, 2024. Revenues for the second quarter of 2024 are expected to be $7.2 million to $7.4 million, the highest quarterly revenues in the Company's history. This is up 92% to 97% over t.

Myomo Reports Preliminary Second Quarter 2024 Revenues and Operating Metrics

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024. Management's presentat.

Myomo to Present at the Sidoti Virtual Investor Conference on June 12-13, 2024

Myomo, Inc. (NYSE:MYO ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Scott Henry - AGP Anthony Vendetti - Maxim Group Sean Lee - H.C. Wainwright Ben Haynor - Lake Street Capital Markets Edward Woo - Ascendiant Capital Operator Good day, and welcome to the Myomo First Quarter 2024 Earnings Conference Call.

Myomo, Inc. (MYO) Q1 2024 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2024. Financial and operational highlights for the first quarter of 2024 include the following (all comparisons are with the first quarter of 2023): Total and product revenue was $3.8 million, up 9.

Myomo Reports First Quarter 2024 Financial Results

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (“CMS”), through their regional contractors known as the DME MACs, have remitted and paid lump sum reimbursements to the Company and are beginning to reimburse orthotics and prosthetics (“O&P”).

Myomo Announces First Lump Sum Reimbursements for MyoPros Delivered to Medicare Part B Beneficiaries Under New CMS Fees

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call the same day, Wednesday May 8, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief e.

Myomo to Report First Quarter Financial Results on May 8, 2024

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 ye.

Myomo Appoints Heather Getz to its Board of Directors

Myomo offers revolutionary MyoPro braces that enhance mobility for upper limb disabilities due to various neurological conditions. The company is experiencing a record number of orders, leading to sustainable revenue growth and expansion in the Chinese and German markets. Myomo's strategic focus includes scaling operations globally and investing in R&D to remain competitive and innovate in medical orthotics.

Myomo's Revolutionary MyoPro Brace: A Buy In Neurological Mobility Aid

Medicare decision created a multi-decade revenue growth opportunity. Soft Q1 guidance due to non-recurring timing issues. 2024 guidance gives only partial-year credit to reimbursement change.

News for Myomo Stock (MYO)